{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:03:35Z","timestamp":1774393415026,"version":"3.50.1"},"reference-count":49,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>IgA nephropathy (IgAN) is the most common primary glomerular disease in adults. In recent years, there have been many significant advances in treating IgAN, with multiple successful clinical trials. We aim to determine the comparative effectiveness of available pharmaceutical interventions for treating IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic review and network meta-analysis (NMA) will be conducted to assess the comparative effectiveness and safety of various pharmacological interventions available for adults with IgAN. All randomised controlled trials (RCTs) or quasi-RCTs which have evaluated pharmacological interventions in IgAN will be included. Both published studies and those available only as conference abstracts will be considered. A systematic literature search will be conducted using Ovid MEDLINE(R) ALL, Embase, Cochrane Kidney and Transplant Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry and ClinicalTrials.gov from inception to the present. Data extraction and risk of bias assessments using Cochrane Risk of Bias 2.0 will be performed by two reviewers independently, and differences resolved through consensus. Primary outcomes assessed will be kidney function and death, and secondary outcomes will be cardiovascular disease, other adverse events and patient-reported outcomes. The NMA will be conducted using a Bayesian NMA with Markov Chain Monte Carlo simulation methods in a random-effects model framework. The certainty of the evidence will be assessed using the Confidence In Network Meta-Analysis(CINeMA) tool to manage the Grading of Recommendations, Assessment, Development and Evaluations(GRADE) assessment.<\/jats:p>\n                    <jats:p>After initial publication, the NMA will be maintained as a \u2018living model\u2019 in an open-source web application. A living \u2018auto-search\u2019 will be created and updated monthly to identify new evidence as it becomes available for synthesis. If new relevant studies are identified, after risk of bias assessment, data will be extracted and incorporated into the model, and findings will be updated accordingly. This will potentially provide a continuous overview of the rapidly changing therapeutic landscape of IgAN in the coming years and in future may help us to design \u2018living guidelines\u2019 for the management of IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The findings will be published in international peer-reviewed journals. No results are being presented in this protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251050367.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106553","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:25:24Z","timestamp":1756315524000},"page":"e106553","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-9912","authenticated-orcid":false,"given":"Soumita","family":"Bagchi","sequence":"first","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India"}]},{"given":"Armando","family":"Teixeira-Pinto","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"given":"Nida","family":"Saleem","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia"}]},{"given":"Anh","family":"Kieu","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"given":"Giovanni","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy"}]},{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-4185","authenticated-orcid":false,"given":"Chandana","family":"Guha","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0453","authenticated-orcid":false,"given":"Nicole Jane","family":"Scholes-Robertson","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"given":"Edmund","family":"Chung","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"given":"David","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}]},{"given":"Germaine","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Renal and Transplantation Medicine, Westmead Hospital, Westmead, New South Wales, Australia"}]}],"member":"239","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2025123106482292000_15.8.e106553.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.05.013"},{"key":"2025123106482292000_15.8.e106553.2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/nep.12629","article-title":"Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study","volume":"21","author":"Zhang","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"2025123106482292000_15.8.e106553.3","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025123106482292000_15.8.e106553.4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2025123106482292000_15.8.e106553.5","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-3-7"},{"key":"2025123106482292000_15.8.e106553.6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526"},{"key":"2025123106482292000_15.8.e106553.7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a New International Risk-Prediction Tool in IgA Nephropathy [Erratum in: JAMA Intern Med. 2019 Jul 1;179(7):1007. doi: 10.1001\/jamainternmed.2019.2030]","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025123106482292000_15.8.e106553.8","doi-asserted-by":"publisher","DOI":"10.1681\/asn.0000000000000242"},{"key":"2025123106482292000_15.8.e106553.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02038.x"},{"key":"2025123106482292000_15.8.e106553.10","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106482292000_15.8.e106553.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.04.094"},{"key":"2025123106482292000_15.8.e106553.12","doi-asserted-by":"crossref","first-page":"C243","DOI":"10.1152\/ajpcell.00147.2023","article-title":"Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?","volume":"325","author":"Lee","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"2025123106482292000_15.8.e106553.13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"2025123106482292000_15.8.e106553.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4"},{"key":"2025123106482292000_15.8.e106553.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409415"},{"key":"2025123106482292000_15.8.e106553.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062736","article-title":"The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study","volume":"8","author":"Szeto","year":"2013","journal-title":"PLoS One"},{"key":"2025123106482292000_15.8.e106553.17","doi-asserted-by":"publisher","DOI":"10.1159\/000013619"},{"key":"2025123106482292000_15.8.e106553.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311804"},{"key":"2025123106482292000_15.8.e106553.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-006-0433-8"},{"key":"2025123106482292000_15.8.e106553.20","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","article-title":"Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT","volume":"33","author":"Shima","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2025123106482292000_15.8.e106553.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.01.026"},{"key":"2025123106482292000_15.8.e106553.22","doi-asserted-by":"publisher","DOI":"10.1159\/000331453"},{"key":"2025123106482292000_15.8.e106553.23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11255-019-02329-5","article-title":"Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria","volume":"52","author":"Xiaowei","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"2025123106482292000_15.8.e106553.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"2025123106482292000_15.8.e106553.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362"},{"key":"2025123106482292000_15.8.e106553.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926517","article-title":"Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review","volume":"13","author":"Liao","year":"2022","journal-title":"Front Immunol"},{"key":"2025123106482292000_15.8.e106553.27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"The Lancet"},{"key":"2025123106482292000_15.8.e106553.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.09.017"},{"key":"2025123106482292000_15.8.e106553.29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison","volume":"99","author":"Ismail","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025123106482292000_15.8.e106553.30","first-page":"35","article-title":"Off-Label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis","volume":"56","author":"Feng","year":"2025","journal-title":"Am J Nephrol"},{"key":"2025123106482292000_15.8.e106553.31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2025123106482292000_15.8.e106553.32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102810","article-title":"New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J Clin Med"},{"key":"2025123106482292000_15.8.e106553.33","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"2025123106482292000_15.8.e106553.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305635"},{"key":"2025123106482292000_15.8.e106553.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"2025123106482292000_15.8.e106553.36","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718"},{"key":"2025123106482292000_15.8.e106553.37","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1159\/000496000","article-title":"Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis","volume":"43","author":"Yang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2025123106482292000_15.8.e106553.38","article-title":"Immunosuppressive agents for treating IgA nephropathy","volume":"3","author":"Natale","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106482292000_15.8.e106553.39","article-title":"Non-immunosuppressive treatment for IgA nephropathy","volume":"2024","author":"Tunnicliffe","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106482292000_15.8.e106553.40","unstructured":"Cochrane . Available: https:\/\/www.cochrane.org\/news\/new-cochrane-handbook-systematic-reviews-interventions [Accessed 04 Mar 2025]."},{"key":"2025123106482292000_15.8.e106553.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"2025123106482292000_15.8.e106553.42","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07840621"},{"key":"2025123106482292000_15.8.e106553.43","unstructured":"ICH . Available: https:\/\/www.ich.org\/page\/efficacy-guidelines [Accessed 17 Mar 2025]."},{"key":"2025123106482292000_15.8.e106553.44","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000135"},{"key":"2025123106482292000_15.8.e106553.45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025123106482292000_15.8.e106553.46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025123106482292000_15.8.e106553.47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-0716-1566-9_7","article-title":"Living Systematic Reviews","volume":"2345","author":"Simmonds","year":"2022","journal-title":"Methods Mol Biol"},{"key":"2025123106482292000_15.8.e106553.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k585","article-title":"Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study","volume":"360","author":"Nikolakopoulou","year":"2018","journal-title":"BMJ"},{"key":"2025123106482292000_15.8.e106553.49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/eurjcn\/zvae048","article-title":"A practical guide to living evidence: reducing the knowledge-to-practice gap","volume":"24","author":"Allida","year":"2025","journal-title":"Eur J Cardiovasc Nurs"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:51:10Z","timestamp":1767192670000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2025-106553"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106553","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}